Astellas, Medivation reach licensing deal for prostate cancer drug
Medivation could receive as much as $765 million from a licensing deal with Astellas Pharma for its prostate cancer drug candidate MDV3100. Astellas Pharma plans to market the treatment in countries other than the U.S., where Medivation will have co-development and commercialization rights.
Bloomberg | 10/28
This story published in BIO SmartBrief on 10/28/2009
More from SmartBrief:
3 Maxygen execs to depart after forming Astellas joint venture
Wednesday, July 1, 2009
MRSA drug telavancin gains FDA approval
Monday, September 14, 2009
Ironwood Pharmaceuticals files plans to go public
Monday, November 23, 2009
Get stories like these delivered daily for FREE:
|
BIO SmartBrief
Designed specifically for biotechnology industry professionals like you, BIO SmartBrief is a FREE daily e-mail newsletter. It provides the latest news and information you need to stay informed about important biotech issues. Learn more |
|